{"id":1932,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-06-28","marketCap":8219.23,"name":"Karuna Therapeutics Inc","phone":"18574492244","outstanding":37.73,"symbol":"KRTX","website":"https://karunatx.com/","industry":"Biotechnology"},"price":217.045,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Market Capitalization and Valuation Metrics of Karuna Therapeutics Inc Compared to Industry Benchmarks","date":"2023-12-14","url":"/posts/2023/12/14/KRTX","content":[{"section":"Market Capitalization","text":"As of the latest data available, Karuna Therapeutics Inc has a market capitalization of approximately $1.5 billion."},{"section":"Valuation Metrics","text":"To evaluate the valuation of Karuna Therapeutics Inc, we can consider several relevant metrics."},{"section":"Price-to-Earnings (P/E) Ratio","text":"The P/E ratio compares the price per share of a company's stock to its earnings per share. At present, Karuna Therapeutics Inc has a P/E ratio of X, which can be compared to the average P/E ratio of companies in the same industry."},{"section":"Price-to-Sales (P/S) Ratio","text":"The P/S ratio measures a company's stock price relative to its revenue. Currently, Karuna Therapeutics Inc has a P/S ratio of X, which can be compared to industry benchmarks."},{"section":"Price-to-Book (P/B) Ratio","text":"The P/B ratio compares the market value of a company to its book value. For Karuna Therapeutics Inc, the P/B ratio is X, indicating how the stock price relates to the company's assets and liabilities."},{"section":"Earnings per Share (EPS)","text":"Karuna Therapeutics Inc's latest reported earnings per share is $X. This metric can be analyzed in conjunction with the P/E ratio to assess the profitability and valuation of the company."},{"section":"Dividend Yield","text":"Karuna Therapeutics Inc does not currently offer a dividend yield, as it may be reinvesting its earnings for growth opportunities."},{"section":"Conclusion","text":"In summary, Karuna Therapeutics Inc has a market capitalization of approximately $1.5 billion and can be evaluated using various valuation ratios. These include the P/E ratio, P/S ratio, P/B ratio, EPS, and dividend yield. Comparisons to industry benchmarks are essential to determine if the company's stock is overvalued, undervalued, or in line with its peers."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1702441082,"headline":"Deutsche Bank Initiates Coverage of Karuna Therapeutics (KRTX) with Buy Recommendation","id":124476802,"image":"","symbol":"KRTX","publisher":"Fintel","summary":"","url":"https://fintel.io/news/deutsche-bank-initiates-coverage-of-karuna-therapeutics-krtx-with-buy-recommendation-170"},{"category":"company","date":1702379160,"headline":"Where Karuna Therapeutics Stands With Analysts","id":124497694,"image":"","symbol":"KRTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253457511"},{"category":"company","date":1702344360,"headline":"Karuna Therapeutics initiated with bullish view at Citi, here's why","id":124497695,"image":"","symbol":"KRTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253653480"},{"category":"company","date":1702265640,"headline":"Karuna Therapeutics initiated with bullish view at Deutsche Bank, here's why","id":124447440,"image":"","symbol":"KRTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251984748"},{"category":"company","date":1702053044,"headline":"Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?","id":124394611,"image":"https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b","symbol":"KRTX","publisher":"Yahoo","summary":"Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","url":"https://finance.yahoo.com/news/fate-therapeutics-fate-10-3-163044754.html"},{"category":"company","date":1701946860,"headline":"After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next","id":124364696,"image":"","symbol":"KRTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246149346"},{"category":"company","date":1701935520,"headline":"AbbVie – Cerevel M\u0026A deal lifts Reviva, Karuna","id":124361248,"image":"","symbol":"KRTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3245898505"},{"category":"company","date":1701880238,"headline":"Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?","id":124336733,"image":"https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926","symbol":"KRTX","publisher":"Yahoo","summary":"Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","url":"https://finance.yahoo.com/news/why-halozyme-therapeutics-halo-2-163038931.html"},{"category":"company","date":1701422580,"headline":"The most crowded pharma longs and shorts, according to UBS","id":124225161,"image":"","symbol":"KRTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3237004451"},{"category":"company","date":1701417060,"headline":"Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Karuna Therapeutics (KRTX) and Argenx Se (ARGX)","id":124226087,"image":"","symbol":"KRTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3236901230"},{"category":"company","date":1701363240,"headline":"FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug","id":124205690,"image":"","symbol":"KRTX","publisher":"Yahoo","summary":"If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.","url":"https://finance.yahoo.com/news/fda-accepts-karunas-krtx-nda-165400418.html"},{"category":"company","date":1701319260,"headline":"Analysts’ Top Healthcare Picks: Cigna (CI), UnitedHealth (UNH)","id":124202208,"image":"","symbol":"KRTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3234808628"}]}